Member Info for SocialistB

This share was once predominantly for chancers and might still be so for a few more days until we get news to HG-CT-1's efficacy.

But we got the news Monday morning at 0700, they have not inject the first Patient the middle of the night over there.

It was done sometime last week and the absence of bad news bodes very well in my ears as I was worried about the first 48 hours.

Question is when will we see a different group of risk takers?

Already now, or first when we get news that it works?

Which can be in as little as 7 days as I have understood it.

Tick tock

A big thank you to JustHereForHemo et alia for securing further funds for HEMOGENYX.

In the last couple of days I noticed an uptake in posts of what I'll characterize as bad intentions, so I feared a Peterhouse special was coming our way.

It didn't.

Instead we got a CLN arrangement.

When I saw the RNS mentioning CLNs I was not pleased as I have a strong aversion to CLNs; they often evoke a sense of skepticism in me. However, after careful consideration of the current proposal, I must admit that what has come to the table is nothing short of a fantastic deal.

Usually, my instinct when encountering CLNs is to consider selling rather than holding. The complexities and potential pitfalls associated with them often overshadow any perceived benefits. Yet, this time feels different. The structure of this particular offering appears robust and strategically sound, as it serves as an effective way of raising capital while still protecting the company from the dangers I normally associate with CLNs.

Unfortunately, I was not aware of what was happening behind the scene, so my ability to contribute financially has been limited; however, I have done my part by actively participating in the open market today to help raise our share price.

On a lighter note, I would like to sarcastically thank those shorters who provided me with such a low entry point! Your actions have inadvertently allowed me to acquire shares at an advantageous price, which I genuinely appreciate.

With money in the bank and the ability for HEMOGENYX to raise more from willing investors, we just await positive results from the trail, which hopefully will result in a higher share price.

That is in everyone's best interest, Patient and investors alike.

Well, maybe not everyones interest, not the shorters that is for sure and maybe not big pharma that would like to buy a successful medical candidate for peanuts.

Years back, Hemogenyx created a mouse model that mimics the human immune system.

They have tested their HG-CT-1 on this model and got some awesome results

HG-CT-1 is designed for the treatment of acute myeloid leukemia (AML) and designed to attack cancer cells specifically expressing CD33, a protein commonly found on the surface of leukemic cells, particularly in AML.

The test on the mice demonstrated that HG-CT-1 effectively eradicated AML cells in mice.

I fully accept that there is a difference between mice and humans, but the mice were engineered to mimic the human immune system.

For that reason I believe that Hemogenyx's HG-CT-1 has an above average change of success.

For the benefit of patients with AML and I am not shy to admit my wallet, I hope that it is successful.

But if it is not then we still got CBR.

HEMO is not just a one trick pony.

I asked ChatGPT the following question:

Succes rate of pharmaceutical products passing phase 1 trials and only phase 1

And the answer was:

The success rate of pharmaceutical products passing Phase 1 trials is generally higher than in later stages. However, specific statistics can vary based on the type of drug, therapeutic area, and other factors. On average, the success rate for drugs moving from Phase 1 to later phases is estimated to be around 60-70%.

Phase 1 trials are primarily concerned with assessing the safety, dosage, and pharmacokinetics of a drug. The focus is not on efficacy but on how the body absorbs, distributes, metabolizes, and excretes the drug.

Since Phase 1 trials often involve healthy volunteers and focus on safety rather than therapeutic outcomes, the failure rate is lower than in subsequent phases where the drug's efficacy and broader safety profile are tested in larger patient populations. However, drugs that succeed in Phase 1 do not always continue to succeed in later phases, as they may fail in Phase 2 or Phase 3 due to efficacy or safety concerns.

HEMOGENYX'S is however not purely a phase 1 trial, it is not tested on a healthy individual.

But on a person with cancer and in dire need for it to work.

So let's hope it does.

And based on the information that I have heard over the last couple of years, especially how it works on the mice specifically designed for this purpose, I am very optimistic.

@Hulver

As to what will happen, who knows?

I guess it depends on how many troubles lie ahead of us.

I hope that HG-CT-1 works and soon generates income while still going through the various phases since there are limited, if any, other alternatives for Patients out there.

And that Hemogenyx and Kure.AI then managed to reduce the production time to 1 day in the near future as well.

If that is too much to hope for on its own, then at least new investors start to dip their toes 48 hours after the first injection, and there is no sign of uncontrollable side effects. They then pile in seven days after that when we hopefully get the first news that HG-CT-1 is showing positive results.

New investors mean dilution, and that is needed as long as we are not cash-generating or not generating enough cash to pursue CBR and CDX.

I hope to keep it all in-house; I hope that is also the intention of the BOD.

The wish to keep it all in-house might be too optimistic of me, so I am open to a good JV.

If that fails, a sale of HG-CT-1 for a good price would not go amiss.

But, yeah, my dream is to manage to keep it all.

So, yesterday, old as well as new names appeared.

They seem to have one thing in common.

Dissing the potential here.

Why.

And how come they all appear on the same day.

Could it be a pure coincidence?

Have they sat on the sideline, eager to come with their input, but not dared until others started and felt more safe to join?

Was it a coordinated front agreed behind closed doors?

A troll farm that has been engaged?

If so, by whom?

Just an individual hoping to lower the entry price?

Or is it more sinister, someone who wants to do their best to hinder Hemogenyx raising enough capital to prove up their candidates?

What's your thoughts?

@Digittt

No offence taken as you have clearly misunderstood what I was saying.

That happens even to the best of us:-)

I do not recall where I got the impression that Hemogenyx are of the opinion they got “really good preliminary results,” regarding HG-CT-1.

Quite frankly, I am unsure if it is mentioned in a RNS, video call or if it's just a claim made on this board.

But none the less, I'm of the impression that Hemogenyx is very pleased with the results they have had in Petri dishes, HEMO MICE, and most likely as of lately AI.

Taking all this into the round, I think there is really good chances that after 7-14 days there will be a reduction in AML blasts in the peripheral blood as mentioned by Haywain earlier this morning.

So, if nothing unforseen happens in the first 48 hours after injection, I think it will go well.

And for that very reason, my deepest respect and gratitude to Patient 1, going into uncharted territory.

I think it is worth to pay special attention to the following part 3/4 down the page

Secondary Outcome Measures

Estimate the efficacy of HG-CT-1 cells as defined by clinical response according to established criteria for AML.

Proportion of subjects with response, according to ELN 2022 criteria. {Dohner et al., 2022 #29518}. To demonstrate the anti-AML activity of HG-CT-1.

Day 14, Day 28, Month 3, Month 6 and Month 12

Already at day 14 they will measure the anti-AML activity of HG-CT-1.

If we can get through the first 48 hours without any issues, it will be a positive sign. I mention this because this is the first time this procedure is being tested on a human, and there could be differences compared to all the testing that has occurred beforehand. However, I believe the preparations are strong, and I hope that, therefore, it is unlikely that we will encounter any significant problems.

So, if no news are coming out in the first 48 hours and then we get positive news 14-16 days later, then all should be awesome.

@JustHereForHemo

Thank you for your comprehensive reply.

Regarding the Mcap and fundraising, keeping Hulvers post regarding BriaCell in mind from the other day.

My best suggestion to avoid a potentially negative scenario in that regard is to become cash generating.

So, I am all in favour of keeping HG-CT-1 in house, wether HEMO manages to reduce the production time to 1 day or not.

If the company becomes cash generating, we might have enough funds to progress, do not forget that everything has been achieved on a shoestring so far, so might be able to continue to do so, although not desirable.

However a continuous monthly income will be extremely comforting.

Maybe a small reasonable debt can be obtained to kickstart the lined up CBR candidates.

That way around, we are not the victim of a poor performing share price.

But can take advantage of the market when is positive

@longshorttrade, regarding your 0844 post.

The company will only be bought out if the majority of shareholders sell up.

My hope is that the majority won't and are more interested in getting closer to the true value of our assets.

I get that it is tempting to accept money in the pocket, right here right now.

But it will only be peanuts compared to the actual worth of the company's assets, if they works

And we will know in a matter of weeks/months if the 1st Patient has gone into remission.

If that happens, then the share price ought to shoot up, but since this is HEMO and it should have happened a long time ago, who knows:-(

What is the realistic future value of HEMOGENYX?

Eli Lilly sell around 52 products

https://www.drugs.com/manufacturer/eli-lilly-and-company-81.html

I think we recently talked about Eli Lilly being worth over 700 Billion.

Now some totally rudimental calculations, but based on the above facts and some assumptions.

HEMO has HEMO CAR-T, CDX and CBR and we know from a previous RNS that there is more CBR specific candidates (it was mentioned in plural) in the pipeline when funding allows.

So let's just say that it amounts to at least 5 candidates and lets allow ourselves the fancyfil assumption that they all work in 10-15 years time and are cash generating.

That's just shy of 1/10th of the candidates that Eli Lilly has and for that reason, in my rudimental calculations, I allow myself to increase HEMOGENYX's value to 1/10th of Eli Lilly's value, so that would then amount to the region of 70 Billion dollars.

(Taking liberties, yes I am aware, but as an avid believer in CBR's ability, I think it is a conservative goal)

We can't get there without either income or funding.

Income can be sorted by selling a candidate (but that will affect the valuation) or even better turn a candidate into a cash generating asset.

With HEMOGENYX'S latest collaboration to reduce production time to one day, if this is successful, it could become a reality.

The third option is funding, IE dilution.

I hope that HEMOGENYX'S can sell into an ever increasing share price, based on continuous good results as the candidates matures.

With a bit of luck, we will not exceed 10 Million shares, by the time all 5 assumed candidates reach the market (if they work, that is)

Now based on this dream (but not totally implausible) scenario, what serves the current shareholders best?

Accepting 2.5 Billion to 14 Billion while still in the phase 1-3 stage, and possible only with 5 Million shares in circulation?

Or wait, 10-15 years and enjoy the continuous growth of the company's share price to a market cap of the assumed sum of 70 Billion?

2.5 Billion / 5 Million equal 500 Dollar a share

14 Billion / 5 Million equal 2800 Dollar a share

70 Billion / 10 Million equal 7000 Dollar a share.

For various options to happen, we need the candidates to be successful and there is a real risk they won't all be, just because that is how it often goes in medical research.

So what is your aptitude for risk Vs potential reward?

I know that much as I intend to still be a proud shareholder 15 years from , I'll be buying and selling along the journey as it is unlikely to go up in a straight trajectory and I'll want to enjoy the finer things life has to offer, before I get a cancer HEMOGENYX can't cure.

@Barbershop

Thank you for your explanation.

There is stuff there that I am unaware of and will have to research.

@Barbershop.

Given that you have 2 investments listed on Nasdaq, that have been doing very well there for the past 6 months, why are you first now changing your mind that it might do HEMOGENYX very well to eventually get listed in the USA.

Not that that is on the cards at present, but hopefully sometime during 2025-2026, if it is easier for the company to raise investments in the USA.

@Saint68

I share your fear that we can be bought for peanuts.

Look at Tillywiz's post from yesterday at 1200.

Here follows an extract:

"Stock on loan / Shorts -

Current - 1.5 k

Wednesday 7.8 k

reduced 6000 on Thursday / Friday so some of those buys were certainly shorts closing - good sign 👍👍

( value reduced from £70, 000 to £6500 currently ."

To me it is scary that there was actually enough sellers at these prices to close the shorts without it having a more profound positive effect on the share prize.

But, for at entity to reach 50 percent they have to buy a lot of shares and the more of us who are sitting tight the better for the upward trajectory of the share price.

Let's all not forget what Mr Sandler once said, if I remember correctly, years and Billions.

For arguments sake, let's say that with 5 million shares in issue and a value of the candidates at 2 Billion (the lowest plural of Billion:-) it amounts to 400 pounds a share.

If we go by 10 million shares in issue to secure the full funding needed over the years, then it's gotta equal 200 pounds a share.

In the end it is up to us share holders how cheaply we want to cash out, either because we want to or have to.

It is my sincere opinion and belief that if CBR works as it says on the tin (or our wishfull thinking, take your pick) then 2 Billion is but a drop in the ocean of the future value of this company.

So let's get funding sorted, so Hemogenyx can move on with the clinical research, which will hopefully at some point result in an increased share price, making any hostile takeover more difficult, or at the very least vastly expensive.

So a little prayer to all shareholders, please do not sell any more shares cheaply then you absolutely have to.

@Saint68

It sounds like we agree on a lot things, just put the emphasis differently.

And I say that knowing fully well, I might be to pedantic stressing the various words, but semantics are important.

(But not so important it's worth risk turning a conversation with a valued contributor into a mudslinging match)

We fully agree that any entity or entities acting in concert is OBLIGATED to make an offer when they reach 30 percent.

Those rules are there to protect the rest of us.

In theory you can easily imagine that an entity would love to own a huge percentage of a well run company or one with a bright future ahead of them.

The higher their stake the better, simple logic.

But the moment they pass the tresshold of 30 percent they are OBLIGATED to submit an offer for the rest of the company.

And that is not just coming up with a number out of the blue and they'd need the finance behind them.

So for most entities its best to keep it below 30 percent to avoid the OBLIGATION being forced upon them, because that is what it is.

So, to me there is no fear of the number 30.

The rest of us can easily fight that off.

We just have to say no.

The fear is 50 percent + 1 share, because that is all it takes to have a majority.

@saint68

everything is ****ible in theory.

but do not forget what the takeover code is about.

it's an obligation.

it's not about gaining a right.

we all have the right to come with an offer, i don't think you even have to own a single share to put an offer on the table.

but while we all might have the right to put an offer on the table, we do not all have the finances in order to do so.

@Saint68

Regarding your post 3-1-2025 @2059.

I am unsure exactly what is meant with that post, maybe mostly because I from time to time hear about a forced takeout offer from various posters.

If you mean that there literally is a risk that the BOD are going to sell the whole allocated 50 percent to one buyer, I think I can calm your nerves.

It simply will not happen.

And here's the logic behind that statement.

We know, from a recording at a previous meeting for potential investors that Prevail Partners are seeking other likeminded investors to join them, as they themselves are a committed investor.

That means they are not interested in another party coming along and get 50 percent just like that and then be obliged to make a buyout offer.

That will not benefit Prevail Partners current investment.

And I most definitely expect that Prevail Partners have only started to buy the amount shares they want in the long run.

And Prevail Partners themselves are not interested in buying the full allocated 50 percent.

They are investors in companies, not company owners.

And as soon an entity owns 30 percent of a company they are obliged to put a buyout offer on the table.

And that is not Prevail Partners business model.

They sell their shares at a high premium, that's how they pay their bills.

Some AI research regarding the takeover code stated among other things the following:

"The 30 percent rule states that if an individual or group acquires 30 percent or more of a company’s voting rights, they are required to make a mandatory offer to all remaining shareholders. This rule is designed to protect minority shareholders by ensuring they have an opportunity to exit their investment at a fair price when control of the company changes hands."

Prevail Partners and any other investors at this point want to ensure that if there is a party trying to acquire 30 percent, they will have to pay a hefty premium.

But, please do not forget, if an offer is made one day by a suitor, wheather they own more or less then 30 percent, we are under no obligation to accept an offer.

We, the shareholders decide what price we wanna sell at.

And, I for one am not keen on selling for peanuts.

@ MrIndia and Drutor.

Thanks for the feedback.

Funding is needed, we all know that and we all expect that to happen in the near future.

Should it happen next week, I just happen to think we will get a positive response quicker if we dont get the news first thing Monday morning.

I literally believe that a day or 2 later, could potentially make a huge difference, at least in the short term.

Best to feed the market, when it's hungry for news.

And I literally think it will be hungrier on Tuesday or Wednesday next week, then on Monday.

But Drutor have a very valid point, why would anyone invest huge sums in HEMO CAR-T, right here right now, compared to waiting 5 weeks.

It's a lot safer, waiting for the first feedback on HEMO CAR-T, and then invest if the results are positive.

But HEMOGENYX is more then just HEMO CAR-T, there is every reason to invest in CBR at any point as we are not awaiting any results there in the near future.

In other words, an investment can come at any time because of the potential in CBR.

And why not get in before the awaited good news regarding HEMO CAR-T, I mean you do not invest if you do not believe and hope in a positive outcome.

Call it FOMO, but I believe we will see a significant investment before we know the results.

And then even better and or bigger investments afterwards, unless all is sold out beforehand.

No RNS this morning.

Good, if you ask me.

The commute to work is a breeze.

Ergo, people are not fully back at work yet.

Ergo, highly likely that neither are the financial market.

So, when is it most likely that we will hear about funding?

Next week, the following week, a couple of weeks, bear in mind, HEMOGENYX has just changed secretary.

If, and it is a big if, we are to get great news next week, then I think it will have a better impact if it is first announced Tuesday or thereafter, as people in the various financial institutions, have then had time to settle a bit in at work again.

Any other suggestions for best day and reasons?